OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
03 Mai 2023 - 8:00AM
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease (DED) to address the
significant unmet need in this multi-billion-dollar market, today
announced that two presentations will be given on OK-101 at the
American Society of Cataract and Refractive Surgery (ASCRS 2023) in
San Diego, CA, May 5-8, 2023.
The Company is pleased that Pedram Hamrah, MD, Co-Director of
the Cornea Service and Director of the Center for Translational
Ocular Immunology at New England Eye Center at Tufts Medical
Center, a leading expert on corneal neuropathic pain and DED, will
be presenting both papers at this ASCRS meeting in San Diego. These
presentations will cover pre-clinical and animal model data on
OK-101 in treating DED and Neuropathic Corneal Pain (NCP).
Presentation Details:
Session title: Ocular Surface Disease Presentation
Date: Saturday, May 6, 2023 Session time: 3:30
PM-5:00 PMASCRS Paper ID 92218 Paper Title: OK-101, a
Novel Chemerin Receptor Agonist, Decreased Clinical Signs and
Symptoms and Improved Immune Tolerance in Dry Eye Mouse Model
Session title: Ocular Surface Disease II Presentation
Date: Sunday, May 7, 2023 Session time: 8:00 AM-9:30
AMASCRS Paper ID 92197 Paper Title: OK-101, a Novel
Chemerin Receptor Agonist, Improves Neuropathic Corneal Pain in
Ciliary Nerve Ligation Mouse Model
About OK-101OK-101 is a lipid
conjugated chemerin peptide antagonist of the ChemR23 G-protein
coupled receptor which is typically found on immune cells of the
eye responsible for the inflammatory response. OK-101 was developed
using a membrane-anchored-peptide (MAP) technology to produce a
novel long-acting drug candidate for treating dry eye disease.
OK-101 has been shown to produce anti-inflammatory and
pain-reducing activities in mouse models of dry eye disease and
corneal neuropathic pain; and is designed to combat washout through
the inclusion of the lipid ‘anchor’ contained in the candidate drug
molecule to enhance the residence time of OK-101 within the ocular
environment.
About OKYOOKYO Pharma Limited
(LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to
listing on NASDAQ and on the standard segment of the Official List
of the UK Financial Conduct Authority and to trading on the main
market for listed securities of London Stock Exchange plc. OKYO is
focusing on the discovery and development of novel molecules to
treat inflammatory dry eye diseases and chronic pain. For further
information, please visit www.okyopharma.com.
The person who arranged for the release of this
announcement on behalf of the Company was Gary S. Jacob, Ph.D.,
Chief Executive Officer of OKYO.
Enquiries:
OKYO Pharma
Limited |
Gary S. Jacob, Chief Executive
Officer |
+44 (0)20 7495 2379 |
|
|
|
Investor
Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
|
|
|
Optiva Securities
Limited (Broker) |
Robert Emmet |
+44 (0)20 3981 4173 |
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE
PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF
DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT)
REGULATIONS (SI 2019/310) (UK MAR). UPON THE PUBLICATION OF THIS
ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024